Navigation Links
synthesis in Medical Technology

Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharma's Product Class

... are universal and essential components of protein synthesis machinery found in all organisms, but human ... signaling activities distinct from the protein synthesis activities. In this recently published study, a ... mutations do not cause a loss in the protein synthesis activity, indicating that the neuropathy arises ...

DSM and LibraGen Sign Agreement to Co-Develop Transaminases for Production of Chiral Amines

... and to develop and optimize enzymatic synthesis processes for complex molecules. Financial ... of innovative bioprocesses for molecule synthesis using biocatalysis for fine chemicals, cosmetics ... its customers high performance and competitive synthesis solutions. Since the company was set up in 2001, ...

New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder

... cholic acid (CA), had a significantly higher synthesis rate in people with type 2 diabetes than in ... type 2 diabetes showed a significantly higher CA synthesis rate (15.9 plus or minus 3.1 vs. HC 9.5 plus or ... micro mol/kg; p<0.05) and total bile acid synthesis (28.1 plus or minus 6.7 vs. HC 18.5 plus or minus ...

Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology

... to continue to develop FAB's cell-free protein synthesis technology towards commercialization. During ... vaccines using a proprietary cell-free protein synthesis technology. Cell-free technology has the ... the leader in the field of cell-free protein synthesis by developing its own and collaborative therapies ...

DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug

... 2b clinical trial of DIO-902, a novel cortisol synthesis inhibitor being studied for the treatment of type ... and metabolic syndrome. There are no cortisol synthesis inhibitors on the market today, ... diabetes." About DIO-902 DIO-902 is a cortisol synthesis inhibitor that is being developed as a therapy ...

Aching Back? Cholesterol Medication Might Help

... of nucleus pulposus cells had increased. Lovastatin increased the synthesis of collagen II, a protein that makes up moveable joints, and decreased the synthesis of collagen I, a protein that is related to fibrosis (the formation or ...

febit and TGen Collaborate to Study New DNA Capture Method

... genomic research in the hand of the user. The seamless integration of DNA synthesis and analysis and the superior support in experiment design and ... Geniom exploits cutting-edge microarray technology for analysis and synthesis of genes and genomes, providing superior time- and cost-efficiency ...

Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling

... on glucose homeostasis, including a decrease in gluconeogenesis (glucose synthesis by the liver). These effects have been attributed primarily to activation ... programs are based on proprietary expertise in the rational design and synthesis of natural and synthetic small molecule derivatives targeting FXR, TGR5 ...

Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion

... the use of postmortem tissue. Adlyfe's novel technology is based on the synthesis of conformationally sensitive peptides (chains of amino acids that are ... and other diseases. The Company's novel technology is based on the synthesis of small peptide, or Pronucleon(TM) ligands, that are amino acid sequence ...

Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA

... LX1032 was discovered and developed at Lexicon to reduce serotonin production by inhibiting tryptophan hydroxylase (TPH), a key enzyme in the synthesis of serotonin. Excessive levels of serotonin have been implicated in symptoms associated with carcinoid syndrome. Serotonin's breakdown product, ...

Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications

... on proprietary, naturally occurring, resected human tRNA synthetases. Although tRNA synthetases are universal and essential components of protein synthesis machinery found in all organisms, human synthetases have naturally occurring resected variants with potent cell signaling activities that are vital ...

AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria

... intermittent porphyria is a rare genetic disease in which mutations in the PBGD gene result in insufficient activity of a protein necessary for the synthesis of heme. This leads to an accumulation of toxic intermediate metabolites resulting in a wide variety of problems including acute, severe abdominal ...

Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop

... genetic disorder caused by a deficiency of C1 inhibitor, a human plasma protein. This condition is the result of a defect in the gene controlling the synthesis of C1 inhibitor. C1 inhibitor maintains the natural regulation of the contact, complement, and fibrinolytic systems, that when left unrestricted, can ...

Pelleve Receives FDA Clearance for the Treatment of Mild to Moderate Facial Wrinkles

... This gentle heating of the deeper dermal tissue induces collagen denaturization and contraction. As the dermal tissue recovers, new collagen synthesis occurs, which creates a tightening effect. The result is a noticeable improvement in skin quality and appearance with minimal side effects and ...

SAFC Biosciences(R) and Vivalis Collaborate to Optimize Cell Culture Media for Vaccines Production

... cell culture products and services for biopharmaceutical manufacturing, biochemical production and the manufacturing of complex, multi-step organic synthesis of APIs and key intermediates. SAFC has manufacturing facilities around the world dedicated to providing manufacturing services for companies ...

ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent

... of related chemical compounds. PG301029 is a highly novel transcriptional inhibitor of HCV replication, yielding a significant reduction of viral RNA synthesis in infected cells, and laboratory studies have demonstrated the compound to be less toxic and more active than the FDA approved agent ribavirin. ...

DSM Obtains Exclusive World-Wide License for Innovative Drug Delivery Technology

... employs the Trancerta(TM) Drug Delivery approach which is based on DSM's core strengths in polymers combined with its extensive in-house library of synthesis methods, formulation and processing techniques. DSM's current biomedical portfolio also includes ComfortCoat(TM) hydrophilic and antimicrobial ...

Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting

... severe diarrhea and abdominal discomfort. LX1032 acts to reduce serotonin production by inhibiting tryptophan hydroxylase (TPH), a key enzyme in the synthesis of serotonin. LX1032 is being developed in a product development collaboration with Symphony Capital Partners, L.P. and its co-investors. ...

Adlyfe Strikes Translational Medicine Partnership With Wyeth Pharmaceuticals for Alzheimer's Biomarker Assay

... U.S. and international government sponsors and Burrill & Company and Canaan Venture Partners. The Company's novel technology is based on the synthesis of small peptides, or Pronucleon(TM) peptides, that are amino acid sequence matched to target amyloids of interest. Ligand sequences are selected ...

FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)

... genetic disorder caused by a deficiency of C1 inhibitor, a human plasma protein. This condition is the result of a defect in the gene controlling the synthesis of C1 inhibitor. C1 inhibitor maintains the natural regulation of the contact, complement, and fibrinolytic systems, that when left unrestricted, can ...

Solace Pharmaceuticals Initiates Phase IIa Trial of Glial Cell Modulator SLC022 in Post-Herpetic Neuralgia

... properties. The company made equally rapid progress in optimizing inhibitors of the enzyme GTP cyclohydrolase 1 (GCH1), a key target within the BH4 synthesis pathway, and in identifying additional promising drug targets. Solace Pharmaceuticals also established a two-year collaboration with Professor ...

Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting

... 6, at 9:30 a.m. "Abnormal function of the cells lining blood vessels may contribute to the complications of sickle cell disease. Disruption in the synthesis of nitric oxide, an important regulator of blood vessel relaxation, contributes to these abnormalities," said Nancy Berliner, M.D., 2009 ASH ...

Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

... derivatives and their unique mechanism of action in selected inflammatory and neurodegenerative conditions, Paratek has an active chemical synthesis effort to produce novel and diverse small molecules, with the goal of developing nonantibacterial compounds with improved activity in serious ...

ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals

... is administered at an injection rate of 1 mL per minute. About Hereditary Angioedema HAE is the result of a defect in the gene controlling the synthesis of C1 inhibitor. C1 inhibitor maintains the natural regulation of the contact, complement, and fibrinolytic systems, that when left unrestricted, ...

BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease

... or tetrahydrobiopterin, is a naturally occurring enzyme cofactor that is required for numerous biochemical and physiologic processes, including the synthesis of nitric oxide (NO). NO has been shown to play a key protective role throughout the cardiovascular system and produces multiple positive effects, ...

Paratek to Present Clinical Data in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

... derivatives and their unique mechanism of action in selected inflammatory and neurodegenerative conditions, Paratek has an active chemical synthesis effort to produce novel and diverse small molecules, with the goal of developing nonantibacterial compounds with improved activity in serious ...

Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen

... Mipomersen is a second-generation antisense drug currently in phase 3 development that reduces the production of apoB-100, a protein critical to the synthesis and transport of "bad" cholesterol. In phase 2 studies, mipomersen, a weekly injectable therapeutic, was observed to reduce cholesterol and other ...

Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis

... immune modulation may be effective, such as Crohn's disease, rheumatoid arthritis, and autoimmune uveitis. Peptimmune has put in place high-quality synthesis and analytical methods that provide a superior level of batch-to-batch reproducibility in the manufacturing of PI-2301. Over 400,000 Americans have ...

Hope for Progeria - Successfully Validated on Mice, a Treatment Could Soon be Tested on Children

... to the protein (whilst it is eliminated in normal cells). In order to inhibit or block the toxicity of progerin, the researchers explored the path of synthesis of this fatty acid. In fact, pharmacological molecules are known to block certain stages in this path of synthesis. After several attempts they ...

Genzyme and Isis Complete Licensing of Mipomersen

... in the U.S. About Mipomersen Mipomersen is a second-generation antisense drug that reduces the production of apoB-100, a protein critical to the synthesis and transport of "bad" cholesterol. Mipomersen is currently in phase 3 development for patients with homozygous familial hypercholesterolemia, a ...

Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008

... immune modulation may be effective, such as Crohn's disease, rheumatoid arthritis, and autoimmune uveitis. Peptimmune has put in place high-quality synthesis and analytical methods that provide a superior level of batch-to- batch reproducibility in the manufacturing of PI-2301. Over 400,000 Americans ...

Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements

... and is dedicated to discovering and developing drugs based on antisense technology for worldwide commercialization. The agents specifically block the synthesis of key cancer proteins. Antisense Pharma has been honored with the Bavarian Innovation Award and the German Founders Award. Disclaimer This ...

Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma

... and is dedicated to discovering and developing drugs based on antisense technology for worldwide commercialization. The agents specifically block the synthesis of key cancer proteins. Antisense Pharma has been honored with the Bavarian Innovation Award and the German Founders Award. Disclaimer This ...

TriLink Awarded a Phase II Grant for a Second Hot Start PCR Project

... available on the market." About TriLink TriLink BioTechnologies, Inc. manufactures custom oligonucleotides, nucleoside triphosphates and synthesis reagents for research and diagnostic laboratories. In addition, it offers radiolabeling services, custom chemistry, contract research services and ...

Increases in West Nile Virus Replikin Concentrations Precede Increases in the Number of Human Cases

... human and shrimp respectively. The conservation of specific replikin structures over many years, the detection of new replikins, and the chemical synthesis of replikin vaccines in 7 days, demonstrated for H5N1 and Taura Syndrome viruses, have now also been demonstrated for West Nile Virus. For further ...

Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis

... and market the drug. Mipomersen is a second-generation antisense drug that reduces the production of apoB-100, a protein critical to the synthesis and transport of "bad" cholesterol. Cholesterol can be carried in the bloodstream in a variety of forms, with high-density lipoprotein, or HDL-C, ...

Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months

... revenue reaches $2 billion. Mipomersen is a second-generation antisense drug that reduces the production of apoB-100, a protein critical to the synthesis and transport of "bad" cholesterol. Cholesterol can be carried in the bloodstream in a variety of forms, with high-density lipoprotein, or ...

ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones

... Co. Ltd. The report, authored by Robert W. Buckheit, Jr., Ph.D. (Executive Vice President and Chief Scientific Officer of ImQuest) describes the synthesis of the highly potent pyrimidinedione series and the structural features of the compounds which are responsible for their high level of potency ...

Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin

... and has the capacity to meet our production and quality goals. They are a leader in the manufacture of pharmaceuticals, precious metals and synthesis chemistry." Under the agreement, Heraeus will manufacture picoplatin API to meet cGMP requirements, and be ready to ship commercial quantities of ...

Cardium and Tissue Repair Company's Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.

... resulted in a high rate of complete wound closure. Gene Activated Matrix(TM) (GAM) technology is designed to provide a therapeutic level of protein synthesis at a particular site in the body and can be used in soft tissue such as skin, ligament, tendons and cartilage, as well as hard tissue such as bone. ...
Other Contents
(Date:12/17/2014)... YORK , Dec. 15, 2014  HITLAB ... Good Clinical Practices (GCP) audit to confirm its ... (FDA) regulations. This accomplishment enables HITLAB to conduct ... utilizing the highest principles for patient safety and ... improve global healthcare access, quality, and delivery with ...
(Date:12/17/2014)...  Automation is fundamentally transforming the travel experience ... international borders. Over the past decade, ePassports, biometric ... travelers to self process through border control via ... an increasing number of airports, seaports, and land ... to Maxine Most , Principal at Acuity ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has ... in India 2015-2019" report to their offering. ... this market is the adoption of multimodal biometric ... characteristic of an individual for verification and identification ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
(Date:12/25/2014)... California (PRWEB) December 25, 2014 Helen ... home in Woodland Hills, California after an 8 year ... away on Christmas Eve evening in her home in ... aggressive metastatic breast cancer. , As ... over forty years, she pioneered and championed many of ...
(Date:12/25/2014)... By Dennis Thompson ... -- Very sick children with complex chronic illnesses can receive ... a "medical home," with easy access to a team of ... were less likely to become seriously ill and need either ... received treatment at an enhanced medical home clinic at the ...
(Date:12/25/2014)... Among early stage breast cancer patients who undergo chemotherapy ... will eventually develop leukemia as a result of their ... from a review of more than 20,000 breast cancer ... that the risk for developing treatment-related leukemia, though low, ... "The frequency of bone marrow cancers such as leukemia ...
(Date:12/25/2014)... 2014 Thousands of transvaginal mesh lawsuits ... a number of multidistrict litigations currently underway in U.S. ... LLP reports. According to an Order issued on December ... Joint Status Conference in all of the proceedings on ... directed to submit a proposed agenda to the Court ...
(Date:12/25/2014)... December 25, 2014 Residents at ... Community, recently showed their generous spirit by providing ... Catawba County Parenting Network- Grandparents Raising Grandchildren program. ... gathered around the largest Christmas tree on the ... purchased by residents of the Abernethy Village Association ...
Breaking Medicine News(10 mins):Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Retirement Community Residents Make Impact During Holiday Season 2
Other TagsOther Tags